Currently, there are 2.23M common shares owned by the public and among those 1.96M shares have been available to trade.
The company’s stock has a 5-day price change of 11.95% and 40.50% over the past three months. GTBP shares are trading -63.27% year to date (YTD), with the 12-month market performance down to -64.26% lower. It has a 12-month low price of $1.72 and touched a high of $10.66 over the same period. GTBP has an average intraday trading volume of 25.18K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.83%, 1.17%, and -6.25% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of GT Biopharma Inc (NASDAQ: GTBP) shares accounts for 64.27% of the company’s 2.23M shares outstanding.
It has a market capitalization of $5.71M and a beta (3y monthly) value of 0.69. The earnings-per-share (ttm) stands at -$7.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 28.56% over the week and 15.53% over the month.
Looking at the support for the GTBP, a number of firms have released research notes about the stock. ROTH MKM stated their Buy rating for the stock in a research note on December 02, 2024, with the firm’s price target at $11. H.C. Wainwright coverage for the GT Biopharma Inc (GTBP) stock in a research note released on May 24, 2021 offered a Buy rating with a price target of $25. B. Riley Securities was of a view on April 13, 2021 that the stock is Buy, while ROTH Capital gave the stock Buy rating on March 17, 2021, issuing a price target of $25.
